Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05823116
Other study ID # 83412
Secondary ID R21AI176298
Status Recruiting
Phase Phase 4
First received
Last updated
Start date May 22, 2023
Est. completion date December 2024

Study information

Verified date May 2023
Source University of Kentucky
Contact Alexander H Flannery, PharmD, PhD
Phone 859-562-2766
Email alex.flannery@uky.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Hospitalized adult participants prescribed vancomycin by their treating physician will be randomized to receive vancomycin via continuous or intermittent infusion and measures of kidney function and injury will be collected.


Description:

All study participants regardless of participation status will have been prescribed vancomycin by a treating physician and received a dose per institutional standard of care. Participants will be randomized 1:1 in permuted blocks of 2, 4, or 6 to receive subsequent doses via continuous or intermittent infusion. Participants randomized to intermittent infusion will receive doses per standard of care at infusion rates of 1 gram per hour in every 8,-12, or -24 hour intervals, while participants randomized to continuous infusion will receive a total daily dose infused over a period of 24 hours. Vancomycin concentration will not exceed 5mg/ml and will be infused via central (preferred) or peripheral administration. In order to ensure consistent dosing between study arms, a precision dosing platform will be used by the PI and team to determine total daily doses to best target an AUC of 500 mg x hr/L (range 400-600 mg x hr/L). A single vancomycin concentration will be obtained the following day with Bayesian-guided area-under-the-curve (AUC) monitoring (with dosing adjusted if needed) to ensure vancomycin exposure remains similar between infusion strategies. Both the initiation and discontinuation of vancomycin, as well as any additional therapeutic drug monitoring, will remain at the discretion of the primary clinical team. Glomerular filtration rate (GFR) will be measured on the day of enrollment and day 3 by the administration of 5 ml iohexol (300 mgI/ml) with iohexol plasma concentrations obtained 1 and 4 hours following administration of iohexol. This change in measured GFR between the infusion strategies is the primary outcome of the study. Plasma and urinary markers of kidney function and injury will be obtained the day of enrollment (Day 0) and subsequent days (Days 2-3). If the participant remains on vancomycin 120 hours following enrollment, measured glomerular filtration rate (mGFR) and biomarkers will be assessed again.


Recruitment information / eligibility

Status Recruiting
Enrollment 56
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - = 18 years of age - Hospitalized at University of Kentucky on a medical service (internal medicine or medical intensive care) - Prescribed = 2 doses of vancomycin per treating physician - Be able to provide written, informed consent, or have a legally authorized representative (LAR) responsible for their care able to provide written, informed consent. Exclusion Criteria: - Chronic kidney disease (documented or prior to admission estimated GFR (eGFR) <60 ml/min/1.73m2 using non-race-based creatinine GFR equation) - End stage kidney disease - Stage 1 or higher AKI per Kidney Disease: Improving Global Outcomes (KDIGO) classification (serum creatinine increase = 0.3 mg/dl or 1.5-1.9 times baseline; urine output < 0.5 ml/kg/hr for 6-12 hours) - Receipt of vancomycin within the last 72 hours (not considering the loading dose) - Allergy to iohexol - Uroepithelial tumors - Pregnancy - Prisoner

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Vancomycin Continuous Infusion
A precision drug dosing platform will be used to determine the empiric dosing regimen and the dosing parameter targeted will be an area-under-the-curve (AUC) of 500 mg?hr/L (range 400-600 mg?hr/L). The total daily dose is infused over a period of 24 hours.
Vancomycin Intermittent Infusion
A precision drug dosing platform will be used to determine the empiric dosing regimen and the dosing parameter targeted will be an area-under-the-curve (AUC) of 500 mg?hr/L (range 400-600 mg?hr/L). The dose is infused at rates of 1 gram per hour in every 8, -12, or -24 hour intervals.

Locations

Country Name City State
United States University of Kentucky Lexington Kentucky

Sponsors (2)

Lead Sponsor Collaborator
Alexander Flannery National Institute of Allergy and Infectious Diseases (NIAID)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in measured glomerular filtration rate (GFR) measured via the administration of a small dose of iohexol followed by the collection of blood samples Baseline (Day 0) and Day 3
Primary Change in urinary Kidney Injury Molecule 1 (KIM-1) Measured by urine ELISA test as the change score Baseline (Day 0) and Day 3
Secondary Plasma cystatin C over time Measured by urine ELISA test at baseline, 48-, and 72-hours following the first dose of vancomycin.
Additional measure at 120 hours if the patient is prescribed vancomycin for 120 hours or more.
Baseline up to 5 days
Secondary Urine Clusterin over time Measured by urine ELISA test at baseline, 48-, and 72-hours following the first dose of vancomycin. Additional measure at 120 hours if the patient is prescribed vancomycin for 120 hours or more. Baseline up to 5 days
Secondary Urine Osteopontin over time Measured by urine ELISA test at baseline, 48-, and 72-hours following the first dose of vancomycin. Additional measure at 120 hours if the patient is prescribed vancomycin for 120 hours or more. Baseline up to 5 days
Secondary Urine Kidney Injury Molecule-1 (KIM-1) over time Measured by urine ELISA test test at baseline, 48-, and 72-hours following the first dose of vancomycin. Additional measure at 120 hours if the patient is prescribed vancomycin for 120 hours or more. Baseline up to 5 days
Secondary Change in Urine Kidney Injury Molecule-1 (KIM-1) Measured as the change score, only in the only in subset of patients prescribed 5 or more days of vancomycin Baseline (Day 0) and Day 5
Secondary Vancomycin Area-Under-the-Curve (AUC) target attainment Defined as range 400-600 mg*hr/L. AUC assessed using one concentration Bayesian estimates. Day 1
Secondary Acute Kidney Injury (AKI) over time Using serum creatinine and urine output components of Kidney Disease: Improving Global Outcome (KIDGO) classification Daily up to 10 days
Secondary Phlebitis over time Monitored per standard of care, using phlebitis scores of 0 (no clinical symptoms) to 4. Documented scores above 0 will be classified as phlebitis. Daily up to 7 days
Secondary Infiltration over time Monitored per standard of care, using infiltration scores of 0 (no clinical symptoms) to 4. Documented scores above 0 will be classified as infiltration. Daily up to 7 days
Secondary Acute Kidney Disease measured per Acute Disease Quality Initiative (ADQI) criteria in a subset of participants where AKI does not resolve by 7 days Until hospital discharge, up to 17 days
Secondary Number of Participants with Major Adverse Kidney Events Composite of death, requirement for kidney replacement therapy, or reduction of 25% from baseline estimated glomerular filtration rate. Until hospital discharge, up to 17 days
Secondary Change in measured glomerular filtration rate (GFR) measured via the administration of a small dose of iohexol followed by the collection of blood samples, only in the subset of patients receiving vancomycin for 5 days Baseline (Day 0) and Day 5
See also
  Status Clinical Trial Phase
Recruiting NCT03221023 - Intrawound Vancomycin Prophylaxis for Neural Stimulator Phase 2/Phase 3
Recruiting NCT03456544 - Vancomycin-Associated Acute Kidney Injury: A Cross-Sectional Study From a Multi- Center in China
Not yet recruiting NCT05964114 - First Time Right of Vancomycin N/A
Completed NCT02951702 - Oral Vancomyin for Primary Clostridium Difficile Infection Prophylaxis in Patients Receiving High-Risk Antibiotics Phase 4
Completed NCT05535075 - Model-informed Precision Dosing of Vancomycin in Adults Phase 4
Active, not recruiting NCT04911270 - Clinical Decision Support Tool for Vancomycin Dosing in Children N/A
Recruiting NCT02456974 - Antibiotic Dosing in Pediatric Intensive Care
Recruiting NCT05257070 - The Clinical Validation of a Dried Blood Spot Method for Vancomycin and Creatinine
Enrolling by invitation NCT03585426 - Vancomycin in the Target Site Treatment of Intracranial Infection Phase 4
Completed NCT04756895 - Vancomycin Dose Adjustments Comparing Trough Levels to The AUC/MIC Method Using a Bayesian Approach in a Hospitalized Adult Population N/A
Suspended NCT02590523 - Intracameral Antibiotic Safety Study Phase 3
Completed NCT03806543 - The Influencing Factors of Vancomycin Trough Level and the Rate Achieving the Target Trough Level
Recruiting NCT04758442 - Optimal Dosing of Vancomycin in an Adult Population of Hemato-oncology N/A
Completed NCT04042233 - Intraosseous Vancomycin in Primary Total Hip Arthroplasty - Designing a Protocol Phase 4
Active, not recruiting NCT04666948 - Precision Dosing of Vancomycin in Critically Ill Children Phase 4
Recruiting NCT02667418 - Optimal Treatment for Recurrent Clostridium Difficile Phase 4
Recruiting NCT06069206 - Effect of Direct-from-blood Bacterial Testing on Antibiotic Administration and Clinical Outcomes N/A
Completed NCT03453684 - Pharmacokinetics of Preoperative Vancomycin Phase 4
Recruiting NCT06426836 - Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation (PADECMO) N/A